RxDoctor Payments Data

Jennifer Bertsch, MD

Internal Medicine · New Orleans, LANPI 1265443964

Payments from drug & device makers

$1,539in general payments, 2019–2025

Across 82 payments — averaging $18.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$340
  • AbbVie$260
  • GSK$235
  • Lilly USA, LLC$207
  • Novo Nordisk$72
  • Teva Pharmaceuticals USA, Inc.$52
  • plus $373 from 14 others

What the payments were for

  • Food & beverage$1,539100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,539 in reported general payments places this provider in the 70th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$69,834
Medicare patients
243
Services billed
833

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin122$108,489
OzempicSemaglutide68$65,089
Trelegy ElliptaFluticasone/Umeclidin/Vilanter57$49,791
JanuviaSitagliptin Phosphate55$42,177
EliquisApixaban42$40,627
MounjaroTirzepatide35$36,964
Spiriva RespimatTiotropium Bromide22$17,669
FarxigaDapagliflozin Propanediol16$16,164
MyrbetriqMirabegron24$14,766
XareltoRivaroxaban15$14,246
Tresiba Flextouch U-100Insulin Degludec22$10,593
Lantus SolostarInsulin Glargine,hum.Rec.Anlog50$5,687
Combivent RespimatIpratropium/Albuterol Sulfate11$5,284
Desvenlafaxine Succinate ErDesvenlafaxine Succinate81$4,324
SynthroidLevothyroxine Sodium44$4,140

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Spiriva Respimat, Combivent Respimat$45$131,442155 claims
Novo NordiskOzempic$72$65,08968 claims
GSKTrelegy Ellipta$235$49,79157 claims
PfizerEliquis$340$40,62742 claims
Lilly USA, LLCMounjaro$207$36,96435 claims
AstraZenecaFarxiga$19$16,16416 claims
Astellas Pharma US IncMyrbetriq$14$14,76624 claims
AbbVieSynthroid$260$4,14044 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →